Latest News

Result of General Meeting

06 May 2020

Tiziana Life Sciences plc

("Tiziana" or the "Company")

At the General Meeting of the Company held at 11.00 a.m. on 6 May 2020, the resolutions to seek additional authorities to issue shares, to disapply pre-emption rights, replacement of option grants and adoption...



Read more

TR-1: Standard form for notification of major holdings

06 May 2020

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

...

Read more

Total Voting Rights

01 May 2020

For the purposes of the Disclosure Guidance and Transparency Rules, the Company is required to notify the market of the following:

During the month of April 2020, 906,905 Ordinary Shares were issued to support the allotment and issue of sales of...

Read more

Tiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses

27 April 2020

Combination of nanoparticle-Actinomycin D acting as an anti-viral treatment, with an anti-inflammatory agent may present a potential therapeutic option for COVID-19 patients.

New York/London - April 27, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a...

Read more

Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrome and Acute Myeloid Leukemia

24 April 2020

Nanoparticle Actinomycin formulation minimizes toxicity and enhances tolerability by slow release of drug to control Cmax in blood

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

New York/London - April 24, 2020 – Tiziana Life...


Read more

Issue of Equity and Resulting Total Voting Rights. Update on AIM cancellation and migration to Nasdaq.

24 April 2020

London, New York, 24 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease...

Read more

Page 3 of 13 Previous Next